MichaelE.WilliamsMD

Hematologic Oncology

Professor, Internal Medicine, University of Virginia School of Medicine

Dr. Williams is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
Uva Emily Couric Clinical Cancer Ctr
1240 Lee Street
Charlottesville, VA 22908
Phone+1 434-924-9637

Fax+1 434-243-6086

Dr. Michael Williams is a hematologist/oncologist in Charlottesville, VA and is affiliated with the University of Virginia Medical Center and University of Virginia School of Medicine. He received his medical degree from University of Cincinnati College of Medicine and has been in practice 38 years. He specializes in malignant hematologic disorders with a focus in chronic lymphocytic leukemia, mantle cell and other B-cell lymphomas, and Hodgkin lymphoma.

University of Virginia Medical CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
University of Virginia Medical CenterResidency, Internal Medicine, 1980 - 1983
University of Virginia Medical CenterInternship, Transitional Year, 1979 - 1980
University of Cincinnati College of MedicineClass of 1979

America's Top Doctors for Cancer Castle Connolly, 2005-2021
America's Top Doctors Castle Connolly, 2002-2020
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012
Join now to see all

PubMed

1 citations
Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low-Tumor Burden Follicular Lymphoma.
Brad S Kahl, Opeyemi A Jegede, Christopher Peterson, Lode J Swinnen, Thomas M Habermann
Journal of Clinical Oncology. 2024-03-01
1 citations
In-depth cellular and humoral dynamics of the response to COVID-19 vaccine booster in patients with chronic B-cell neoplasms.
Emily Ayers, Glenda Canderan, Michael E Williams, Behnam Keshavarz, Craig A Portell
Blood Cancer Journal. 2023-07-26
4 citations
PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
Kallesh D Jayappa, Brian Tran, Vicki L Gordon, Christopher Morris, Shekhar Saha
The Journal of Clinical Investigation. 2023-07-03

Abstracts/Posters

Multi-Institution Phase I/Ib Continual Re-Assessment Study to Identify the Optimal Dose of of Ibrutinib (IBR) and Venetoclax (VEN) in Relapsed or Refractory Mantle Cel...
Michael E. Williams, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
60th American Society of Hematology Annual Meeting - 11/30/2018

UVA Cancer Center Receives $5.75 Million to Battle Rare Blood CancersAugust 4th, 2022
ASH Expert NHL Roundtable: Episode 1December 13th, 2019
Adherence to Oral Anticancer Treatment: Priorities in Lymphoma and CLLJune 11th, 2018